Impact of statin use on short- and long-term outcomes in patients with sepsis-induced myocardial injury: insights from the MIMIC-IV database DOI Creative Commons
Yuan Liu, John J. Chen, Ying Yuan

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Март 19, 2025

Sepsis-induced myocardial injury (SIMI) is a critical complication of sepsis, marked by high mortality rates, and lacks effective treatments. The impact statin therapy on in SIMI patients remains unclear. This study aims to explore the association between use patients, focusing both short-term long-term outcomes. A retrospective cohort was conducted extracting patient information from Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Patients were categorized into non-statin groups. 1:1 nearest propensity-score matching (PSM) used balance baseline characteristics. Survival outcomes assessed using Kaplan-Meier analysis robust Cox proportional hazards models understand effects use, type dosage at 28 days, 90 1 year. E-Value unmeasured confounding. total 2,246 meeting criteria enrolled final cohort, with 17.9% receiving statins during their ICU stay. Statin associated significantly lower all time points, as shown analysis. In multivariable regression models, correlated 32% reduction 28-day (HR = 0.68, 95% CI: 0.49-0.94), 29% days 0.71, 0.54-0.93), 28% year 0.72, 0.58-0.90), maintaining significance after adjustment confounders. Simvastatin particularly effective, low-dose linked reduced risk. Subgroup analyses suggested consistent benefits. robustness Our demonstrates that across provides substantial benefits, providing greater advantages compared high-dose formulations.

Язык: Английский

Impact of statin use on short- and long-term outcomes in patients with sepsis-induced myocardial injury: insights from the MIMIC-IV database DOI Creative Commons
Yuan Liu, John J. Chen, Ying Yuan

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Март 19, 2025

Sepsis-induced myocardial injury (SIMI) is a critical complication of sepsis, marked by high mortality rates, and lacks effective treatments. The impact statin therapy on in SIMI patients remains unclear. This study aims to explore the association between use patients, focusing both short-term long-term outcomes. A retrospective cohort was conducted extracting patient information from Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Patients were categorized into non-statin groups. 1:1 nearest propensity-score matching (PSM) used balance baseline characteristics. Survival outcomes assessed using Kaplan-Meier analysis robust Cox proportional hazards models understand effects use, type dosage at 28 days, 90 1 year. E-Value unmeasured confounding. total 2,246 meeting criteria enrolled final cohort, with 17.9% receiving statins during their ICU stay. Statin associated significantly lower all time points, as shown analysis. In multivariable regression models, correlated 32% reduction 28-day (HR = 0.68, 95% CI: 0.49-0.94), 29% days 0.71, 0.54-0.93), 28% year 0.72, 0.58-0.90), maintaining significance after adjustment confounders. Simvastatin particularly effective, low-dose linked reduced risk. Subgroup analyses suggested consistent benefits. robustness Our demonstrates that across provides substantial benefits, providing greater advantages compared high-dose formulations.

Язык: Английский

Процитировано

0